Elastrin Therapeutics Inc., a privately held biotechnology company leveraging a platform technology to develop therapeutics that render calcified tissue and organs supple again, announced the formation
(0)
Elastrin Therapeutics Inc., a privately held biotechnology company leveraging a platform technology to develop therapeutics that render calcified tissue and organs supple again, announced the appointment of Pedro M. Quintana Diez, MD as Chief Medical Officer. Pedro will be responsible for the clinical and regulatory strategy, planning, and execution of the company s clinical development plans. We are delighted to bring someone with Pedro s impressive expertise and experience on board during this exciting time for Elastrin, said Dr. Matthias Breugelmans, CEO at Elastrin Therapeutics. His deep knowledge of cardiovascular research and medicine from both an industry and academic perspective is a strong addition to Elastrin preparing for clinical trials. His experience developing early-stage programs into commercial products will be instrumental developing our novel therapies to reverse cardiovascular disease during the next years declared Prof. Naren Vyavahare, Chief Scientifi